MSK Biomarker Ctte: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK. | The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK. | ||
==Meetings/Call Summaries== | ==Recent Meetings/Call Summaries== | ||
*[[MSK Biomarker Committee Call Summaries]] | |||
*[[Media:2017_09-19_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|09.19.2017 QIBA MSK Biomarker Ctte Call Summary]] | |||
*[[Media:2017_07-18_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|07.18.2017 QIBA MSK Biomarker Ctte Call Summary]] | |||
*[[Media:2017_06-20_QIBA_MSK_Biomarker_Cmte_Call_Summary-FINAL.pdf|06.20.2017 QIBA MSK Biomarker Ctte Call Summary]] | |||
''''' | |||
[[MSK Biomarker Committee Call Summaries Archive]]''''' | |||
==Working Documents== | ==Working Documents== | ||
Revision as of 15:18, 3 November 2017
- Co-chairs: Thomas M. Link, MD, PhD; Xiaojuan Li, PhD
- Secretary: Susan Weinmann
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Recent Meetings/Call Summaries
- 09.19.2017 QIBA MSK Biomarker Ctte Call Summary
- 07.18.2017 QIBA MSK Biomarker Ctte Call Summary
- 06.20.2017 QIBA MSK Biomarker Ctte Call Summary
MSK Biomarker Committee Call Summaries Archive